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It could have been a fine spoof, had John
Markoff’s story “Pentagon redirects its
research dollars” in the New YorkTimes,
appeared under the dateline of April 1, 
but not at 1,500 words on April 2.
The ominous reality of his tale for ITC
scientists and electrical engineers is that
under Dr Anthony Tether, (Stanford 
electrical engineer) Defense Advanced
Research Projects Agency is cutting its
spending at the universities, to focus
on the finance of classified and narrowly
defined projects, which have a more
immediate and forseeable payoff.
It is clearly the end of an era that has
earned for Darpa the reputation of long-
term project funder, giving it that ‘blue
chip’ name for ‘blue sky’ research. 
Coincidentally under this focus, Darpa
has done much to boost a one-time
almost non-existent US compound 
semiconductor industry into a lead global
position.
One casualty of the new focus cited is the
‘network embedded sensor technology’
programme, cut or ended at five US 
university campuses and shifted to mili-
tary contractors. 
That could be good news for compound
companies, but a blow for the students
who make up the sector’s future work-
force. Lead scientists and engineers are
now warning of the long term conse-
quences for the economy, and accusing
the Pentagon of reining in an agency that
has played such a key role in fostering
America’s lead in ITC technology. Darpa
does acknowledge the shift in focus. Of
the computer science research allocation
of $564m in 2001 and $583m in 2004, the
University research share has dropped
from $214m to $123m. 
DARPA, writes Markoff, cites more classi-
fied projects since 9/11; privacy fears and
a basic research shift to advanced weapon
systems development ( another probable
benefit for military compound devices).
But apart from the drying up of funds, 
scientists note that remaining grants carry
more restrictions, and are tightly linked to
deliverables. No more unjustified explo-
ration, no more happy, accidental, labora-
tory discoveries and certainly certainly no
more non-US citizen graduates working on
Darpa projects.
While no-one can doubt that a ‘laser’
focused Darpa will achieve its deliver-
ables, only time will tell whether any other
world players can justify funding long term
R&D in the name of Defence, and by so
doing quietly manage to slip into the 
vacated Darpa top slot as prime economic
promotion engine.
Source:http://www.nytimes.com/2005/04
/02/technology/02darpa.html
Anyone up for Darpa’s
long term funding role?
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